US/UK/Canada

Share

Links

Pick a time period -
Tags ( Active)

Delays within FDA postpones CERAMENT G De Novo decision

Lund, Sweden, 08:00 CET, February 28, 2022 –BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announced that due to internal delays at the U.S. Food and Drug Administration (FDA), the agency has informed BONESUPPORT that a response to the company’s De Novo application for marketing authorization for the antibiotic eluting product CERAMENT G for the indication osteomyelitis (bone infection) will be delayed with a few weeks. For more information contact: BONESUPPORT HOLDING ABEmil Billbäck, CEO+46 (0) 46 286 53 70 Håkan Johansson, CFO

BONESUPPORT Holding AB (publ) – Publishes full year report 2021

Lund, Sweden, 08:00 CET, February 17, 2022 – BONESUPPORT Holding AB (publ), an emerging leader in orthobiologics for the management of bone injuries, today publishes the interim report for the fourth quarter 2021 and the full year 2021. STRONG SALES GROWTH, DESPITE OMICRON BREAK-OUT OCTOBER – DECEMBER 2021 · Net sales increased by 15 percent (21 percent at constant exchange rates) and amounted to SEK 61.4 million (53.2). · The North America (NA) segment reported a sales increase of 22 percent (30 percent at constant exchange rate). · The Europe & Rest of the World (EUROW)

BONESUPPORT HOLDING AB (publ) – Invitation to conference call and webcast for year end report 2021

Lund, Sverige, 10.00 CET, 10 February 2022 – BONESUPPORT HOLDING AB (publ), an emerging    leader in orthobiologics for the management of bone injuries, will publish its year end report for 2021, on the 17 February 2022 at 08.00 am CET. The Company will hold a conference call and an online presentation on the same day at 10.00 am CET. The call will be hosted by Emil Billbäck, CEO and Håkan Johansson, CFO who will present the results and answer questions. The presentation will be held in English. The dial-in numbers for the conference call are:SE: +46 851999383UK: +44 3333009270

Change in number of shares and votes in BONESUPPORT Holding AB (publ)

Lund, Sweden, 09:00 CET, 1 February 2022 – BONESUPPORT Holding AB (publ), an emerging leader in orthobiologics for the management of bone injuries, today announced a change in the number of shares and votes. During January, the number of shares and votes in BONESUPPORT Holding AB (publ) has increased with 35,850 due to the exercise of warrants.   As of 31 January 2022, the number of shares in BONESUPPORT HOLDING AB (publ) amounts to 65,490,522 shares, of which 64,200,522 are ordinary shares with one vote per share and 1,290,000 are series C-shares with one-tenth of a vote per share. The

BONESUPPORT signs distribution agreement with OrthoPediatrics

Lund, Sweden, 15:30 CET, 22-01-13 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announced that the company has entered into a distribution agreement with OrthoPediatrics Corp., a leader in the orthopedic pediatric market, to distribute CERAMENT® BONE VOID FILLER (BVF) to pediatric hospitals within the United States. The contract extends BONESUPPORT’s market access further as it provides CERAMENT BVF access to OrthoPediatrics’ network of 250 pediatric hospitals.     In the US, CERAMENT BVF is indicated for use in pediatric patients ages 9

Change in number of shares and votes in BONESUPPORT Holding AB (publ)

Lund, Sweden, 12:00 CET, 30 December 2021 – BONESUPPORT Holding AB (publ), an emerging leader in orthobiologics for the management of bone injuries, today announced a change in the number of shares and votes. During December, the number of shares and votes in BONESUPPORT Holding AB (publ) has increased with 3,000 due to the exercise of warrants.   As of 31 December 2021, the number of shares in BONESUPPORT HOLDING AB (publ) amounts to 65,454,672 shares, of which 64,164,672 are ordinary shares with one vote per share and 1,290,000 are series C-shares with one-tenth of a vote per share.

Change in number of shares and votes in BONESUPPORT Holding AB (publ)

Lund, Sweden, 12:00 CET, 30 November 2021 – BONESUPPORT Holding AB (publ), an emerging leader in orthobiologics for the management of bone injuries, today announced a change in the number of shares and votes. During November, the number of shares and votes in BONESUPPORT Holding AB (publ) has increased with 10,000 due to the exercise of warrants.   As of 30 November 2021, the number of shares in BONESUPPORT HOLDING AB (publ) amounts to 65,451,672 shares, of which 64,161,672 are ordinary shares with one vote per share and 1,290,000 are series C-shares with one-tenth of a vote per share.

BONESUPPORT Holding AB (publ) – Publishes Q3 2021 Interim report

Lund, Sweden, 08:00 CEST, November 4, 2021 – BONESUPPORT Holding AB (publ), an emerging leader in orthobiologics for the management of bone injuries, today publishes the interim report for the third quarter 2021. BEST SALES QUARTER TO DATE JULY – SEPTEMBER 2021 · Net sales increased by 14 percent (26 percent at constant exchange rates) and amounted to SEK 54.9 million (48.1). · The North America (NA) segment reported a sales increase of 16 percent (34 percent at constant exchange rate). · The Europe & Rest of the World (EUROW) segment reported a sales increase of 12 percent

BONESUPPORT HOLDING AB (publ) – Interim Report Q3 2021 Invitation to conference call and webcast

Lund, Sverige, 10.00 CET, 28 October 2021 – BONESUPPORT HOLDING AB (publ), an emerging leader in orthobiologics for the management of bone injuries, will publish its Interim Report Q3 2021, on the 4 November at 08.00 am CET. The Company will hold a conference call and an online presentation on the same day at 10.00 am CET. The call will be hosted by Emil Billbäck, CEO and Håkan Johansson, CFO who will present the results and answer questions. The presentation will be held in English. The dial-in numbers for the conference call are:SE: +46 850558354UK: +44 3333009030US: +1

BONESUPPORT appoints Michael Wrang Mortensen to EVP R&D and Operations

Lund, Sweden, 11:00 CET, 211011 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, announced today that changes are being made to the management team. On December 1, 2021, Michael Wrang Mortensen will begin the newly installed role of Executive Vice President Research & Development and Operations. Michael holds a PhD degree in Chemistry from University of Copenhagen and an executive MBA from the AVT Business School in Denmark. Michael has 15 years of experience from the Medical Device and Healthcare industry with solid leadership and management

Change in number of shares and votes in BONESUPPORT Holding AB (publ)

Lund, Sweden, 12:00 CET, 30 September 2021 – BONESUPPORT Holding AB (publ), an emerging leader in orthobiologics for the management of bone injuries, today announced a change in the number of shares and votes. During September, the number of shares and votes in BONESUPPORT Holding AB (publ) has increased with 1,354 due to the exercise of warrants.   As of 30 September 2021, the number of shares in BONESUPPORT HOLDING AB (publ) amounts to 65,441,672 shares, of which 64,151,672 are ordinary shares with one vote per share and 1,290,000 are series C-shares with one-tenth of a vote per share.

BONESUPPORT – SUPPLEMENTARY US DENOVO APPLICATION SUBMITTED

Lund, Sweden, 08:00 CET, 28-09-21 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announced that the company has submitted a supplementary De Novo application to the US Food and Drug Administration (FDA) to obtain a market approval for the company’s antibiotic-releasing product CERAMENT® G. The application is specified for the indication osteomyelitis (bone infection) and can potentially result in an approval in Q1 of 2022. In February of this year, the FDA requested further data and clarifications on BONESUPPORT’s DeNovo application. The

Study results on FORTIFY are inconclusive

Lund, Sweden, 19:40 CET, 09 09 21 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announced inconclusive results for the company’s Investigational Device Exemption (IDE) study; FORTIFY. The primary safety endpoint for CERAMENT G was met. The FORTIFY study was initiated in 2017 with the purpose to evaluate the ability of CERAMENT G to improve the treatment outcomes for patients with open tibia fractures G-A II-IIIB. Last patients follow up took place in June 2021. The drop-out rate, defined as difference between enrolled and completed

Change in number of shares and votes in BONESUPPORT Holding AB (publ)

Lund, Sweden, 18:00 CET, 31 August 2021 – BONESUPPORT Holding AB (publ), an emerging leader in orthobiologics for the management of bone injuries, today announced a change in the number of shares and votes. During August, the number of shares and votes in BONESUPPORT Holding AB (publ) has increased with 10,000 due to the exercise of warrants.   As of 31 August 2021, the number of shares in BONESUPPORT HOLDING AB (publ) amounts to 65,440,318 shares, of which 64,150,318 are ordinary shares with one vote per share and 1,290,000 are series C-shares with one-tenth of a vote per share. The

BONESUPPORT Holding AB (publ) – Publishes Q2 2021 Interim report

Lund, Sweden, 08:00 CEST, July 15, 2021 – BONESUPPORT Holding AB (publ), an emerging leader in orthobiologics for the management of bone injuries, today publishes the interim report for the second quarter 2021. 58% SALES GROWTH IN CONSTANT CURRENCY   APRIL – JUNE 2021 ·Net sales increased by 43 percent (58 percent at constant exchange rates) and amounted to SEK 51.8 million (36.2). · The North America (NA) segment reported a sales increase of 35 percent (56 percent at constant exchange rate). · The Europe & Rest of the World (EUROW) segment reported a sales increase

BONESUPPORT HOLDING AB (publ) – Interim Report Q2 2021 Invitation to conference call and webcast

Lund, Sverige, 10.00 CET, 8 July 2021 – BONESUPPORT HOLDING AB (publ), an emerging leader in orthobiologics for the management of bone injuries, will publish its Interim Report Q2 2021, on the 15 July at 08.00 am CET. The Company will hold a conference call and an online presentation on the same day at 10.00 am CET. The call will be hosted by Emil Billbäck, CEO and Håkan Johansson, CFO who will present the results and answer questions. The presentation will be held in English.The dial-in numbers for the conference call are:SE: +46 8 50558374UK: +44 3333009274US: +1 6319131422 PIN

Change in number of shares and votes in BONESUPPORT Holding AB (publ)

Lund, Sweden, 12:00 CET, 30 June 2021 – BONESUPPORT Holding AB (publ), an emerging leader in orthobiologics for the management of bone injuries, today announced a change in the number of shares and votes. During June, the number of shares and votes in BONESUPPORT Holding AB (publ) has increased with 362,096 due to the exercise of warrants.   As of 30 June 2021, the number of shares in BONESUPPORT HOLDING AB (publ) amounts to 65,430,318 shares, of which 64,140,318 are ordinary shares with one vote per share and 1,290,000 are series C-shares with one-tenth of a vote per share. The number

BONESUPPORT receives "breakthrough device designation" for CERAMENT G for the indication trauma

Lund, Sweden, 10:00 CET, 17 06 21 BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announced that the company's antibiotic eluting product CERAMENT G has been categorized as a breakthrough device for the indication trauma by the US Food and Drug Administration (FDA). The categorization “breakthrough device” can be assigned to products that are considered to provide a more effective treatment of severe disease states, where there is no comparable equivalent on the market. The categorization is intended to expedite the regulatory review of

BULLETIN FROM THE ANNUAL SHAREHOLDERS’ MEETING IN BONESUPPORT HOLDING AB ON 20 MAY 2021

Lund, Sweden, 14:00 CET, 20 May 2021 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, has today held its annual general meeting. In the light of the ongoing corona pandemic and in order to minimize the spread of the disease, the general meeting was held only through postal voting, without the possibility to attend in person, in accordance with temporary legislation. The annual general meeting adopted the presented income statements and balance sheets as well as the remuneration report prepared by the Board, and granted discharge of liability to

BONESUPPORT Holding AB (publ) – Publishes Q1 2021 Interim report

Lund, Sweden, 08:00 CET, May 6 2021 – BONESUPPORT Holding AB (publ), an emerging leader in orthobiologics for the management of bone injuries, today publishes the interim report for the first quarter 2021. FEWER SURGERIES IN THE WAKE OF AN INTENSIFIED PANDEMIC   JANUARY - MARCH 2021 · Net sales increased by 3 percent (14 percent at constant exchange rates) and amounted to SEK 44.8 million (43.4). · The North America (NA) segment reported a sales increase of 18 percent (36 percent at constant exchange rate). · The Europe & Rest of the World (EUROW) segment reported a

Change in number of shares and votes in BONESUPPORT Holding AB (publ)

Lund, Sweden, 12:00 CET, 30 April 2021 – BONESUPPORT Holding AB (publ), an emerging leader in orthobiologics for the management of bone injuries, today announced a change in the number of shares and votes. During April, the number of shares and votes in BONESUPPORT Holding AB (publ) has increased with 4,000 due to the exercise of warrants.   As of 30 April 2021, the number of shares in BONESUPPORT HOLDING AB (publ) amounts to 65,068,222 shares, of which 63,778,222 are ordinary shares with one vote per share and 1,290,000 are series C-shares with one-tenth of a vote per share. The number

BONESUPPORT HOLDING AB (publ) – Interim Report Q1 2021 Invitation to conference call and webcast

Lund, Sverige, 10.00 CET, 29 April 2021 – BONESUPPORT HOLDING AB (publ), an emerging leader in orthobiologics for the management of bone injuries, will publish its Interim Report Q1 2021, on the 6 May at 08.00 am CET.The Company will hold a conference call and an online presentation on the same day at 10.00 am CET. The call will be hosted by Emil Billbäck, CEO and Håkan Johansson, CFO who will present the results and answer questions. The presentation will be held in English.   The dial-in numbers for the conference call are: Sweden: +46 8 50558366United Kingdom: +44 3333009267

BONESUPPORT awarded Synthetic Implantable Products agreement with Premier

----- This press release has been modified to comply with the Premier IR guidelines ----- Lund, Sweden, 13.00 CET, 20 April 2021 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, has been awarded a group purchasing agreement for Synthetic Implantable Products with Premier. Effective July 1st, the new agreement allows Premier members, at their discretion, to take advantage of pricing and terms pre-negotiated by Premier for CERAMENT® BONE VOID FILLER. “The awarded contract by Premier is a strong testimony and confirmation of the unique value

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Media